ID   BALM-4
AC   CVCL_5427
SY   BALM 4; BALM4
DR   Cosmic; 999783
DR   Wikidata; Q54753207
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=160894;
RX   PubMed=2939141;
RX   PubMed=2985879;
RX   PubMed=3106068;
RX   PubMed=3159941;
RX   PubMed=3874327;
WW   Info; COPE; -; http://www.cells-talk.com/index.php/page/copelibrary?key=BALM-4
CC   Population: Caucasian.
CC   Doubling time: 60-72 hours (PubMed=160894).
CC   HLA typing: A*02; B*13,44 (PubMed=2939141).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5426 ! BALM-3
OI   CVCL_5205 ! BALM-5
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 18
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   PubMed=160894; DOI=10.1002/ijc.2910240509;
RA   Lok M.-S., Koshiba H., Han T., Abe S., Minowada J., Sandberg A.A.;
RT   "Establishment and characterization of human B-lymphocytic lymphoma
RT   cell lines (BALM-3, -4 and -5); intraclonal variation in the B-cell
RT   differentiation stage.";
RL   Int. J. Cancer 24:572-578(1979).
//
RX   PubMed=2939141; DOI=10.4049/jimmunol.136.11.4311;
RA   Pesando J.M., Graf L.;
RT   "Differential expression of HLA-DR, -DQ, and -DP antigens on malignant
RT   B cells.";
RL   J. Immunol. 136:4311-4318(1986).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   Carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3106068; DOI=10.1002/eji.1830170416;
RA   Shields J.G., Smith S.H., Levinsky R.J., DeFrance T., de Vries J.E.,
RA   Banchereau J., Callard R.E.;
RT   "The response of selected human B cell lines to B cell growth and
RT   differentiation factors.";
RL   Eur. J. Immunol. 17:535-540(1987).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//